IMMUNOTECHOLOGIES CORE

免疫技术核心

• 批准号: 7764477
• 负责人: SCOTT E PLEVY
• 金额: $ 13.82万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-15 至 2014-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7764477
• 关键词: Animal Model; Autoimmune Process; Biological Assay; Biological Markers; Biology; Cells; Client; Clinical; Clinical Trials; Collaborations; Communities; Consultations; Core Facility; Custom; Cyclic Nucleotides; Development; Disease; Eicosanoids; Enteral; Enzyme-Linked Immunosorbent Assay; Epithelial; Equipment; Funding; Gastrointestinal Diseases; Goals; Growth Factor; Human; Human Resources; Immune; Immune response; Immune system; Immunoassay; Immunocompetence; Immunologic Monitoring; Immunologics; Immunosuppression; Immunosuppressive Agents; Immunotherapeutic agent; Industry; Inflammation; Inflammatory; Inflammatory Bowel Diseases; Intervention; Irritable Bowel Syndrome; Laboratories; Liver diseases; Malignant Neoplasms; Measurement; Measures; Mediation; Mesenchymal; Methods; Monitor; Mus; Neoplasms; Organ; Patients; Pharmacotherapy; Phosphoproteins; Play; Price; Procedures; Protein Analysis; Proteomics; Quality Control; Radioimmunoassay; Research; Research Design; Research Personnel; Role; Safety; Serum; Services; Signaling Molecule; Site; System; Techniques; Technology; Therapeutic Intervention; Time; Tissue Extracts; Tissues; Training; Translational Research; Transplantation; United States National Institutes of Health; Vaccination; Vaccines; Validation; assay development; base; cancer immunotherapy; clinical efficacy; cost; cost effective; cytokine; discount; experience; gastrointestinal; immunogenicity; interest; member; new technology; novel; peptide hormone; prospective; reconstitution; repaired; serological marker; symposium; technology development

When the UNC Center for Gastrointestinal Biology and Disease was initially established it emphasized analysis of epithelial transport, grovrth, development, and repair, including control of these functions by subepithelial immune and mesenchymal cells. From the outset, it was recognized that a Core Facility capable of measuring levels of soluble signaling molecules (such as peptide hormones, growth factors, eicosanoids, cytokines, and cyclic nucleotides) would be essential to investigators pursuing these goals. For this reason, an Immunoassay (IA) Core was established, and staffed with a Core Director (Dr. Don Powell) and a Core Technician. In 1991, Dr. Michael Goy replaced Dr. Powell as the IA Core Director. Due to steadily increasing demand for Core services, an additional half-time technician was hired in 2002. In January 2008, Scott Plevy replaced Michael Goy as IT Core Director. The strategic reason for this change was Dr. Plevy's expertise in cytokine biology and quantitative technologies, which historically has comprised the predominant usage of the core. In addition. Dr. Plevy brought new expertise in biomarker development and immune monitoring, which as described, will become new initiatives of the Core based on the prospective needs of CGIBD members. In April 2008, Carlton Anderson became the new IT Core Technician and Assistant Director. Mr. Anderson provides a wealth of laboratory experience and expertise. He has rapidly assimilated techniques for the most commonly requested ELISAs, has been trained on all existing equipment, and has developed, under the guidance of Dr. Plevy, new cost effective technologies for the Core. In parallel with these personnel changes, the objectives ofthe IT Core have also evolved and expanded. As the focus ofthe Center has shifted from diarrheal to inflammatory diseases and cancer, the needs of Center members have shifted and the IT Core has acquired new capabilities. From an initial repertoire of three immunoassays performed for a few investigators, the Core now serves a client base of over 50 laboratories, and offers a sophisticated array of services, including (a) over 50 diffierent types of ELISA and RIA measurements, (b) custom immunoassay development, and (c) quantitative multiplex proteomic analysis that can be adapted to numerous applications. During the last funding cycle, as described elsewhere in this application, the proteomic component ofthe IT Core was eliminated. This decision reflects the existence of multiple cores on campus that provide cost-eff^ective proteomic analysis, and followed polling and approval of CGIBD executive committee who concluded that such technology is no longer a high priority. To provide expanded and significantly more cost-effective services to the CGIBD community. Dr. Plevy initiated new cytokine ELISA development for the most requested cytokine assays based on established technology in CGIBD investigator's laboratories. Mr. Anderson has already negotiated better prices for standard ELISA kits; therefore, CGIBD investigators immediately benefitted by a 10- 35% reduction in costs for services provided. With increased emphasis on translational research, the IT Core has embarked upon several new initiatives. An emphasis of the IT Core moving forward, facilitated by the acquisition of new technology platforms and thematically consistent vnth the NIH Roadmap, will be biomarker development vnth an emphasis on human studies. We are now performing multiplex protein analysis using xMAP technology. We have negotiated vnth Bio-Rad and R and D Systems toreceive discounted prices on multiplex kits for the Core's Bio-Plex 200 system which vnll facilitate human and murine research, and contribute to biomarker development. Additionally, we are planning an on-site symposium to better acquaint investigators with the multiplex platform. We have also established collaboration with Glycominds, Inc. to develop ELISA-based serological markers directed against the enteric microbiota in human inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and inflammatory liver diseases. Finally, as a result of recent NIH funded and industry sponsored activities of several Center investigators, the Core has taken an interest in immune monitoring in IBD patients, including but not limited to, immunogenicity and vaccine monitoring, and immunocompetence and reconstitution during therapeutic interventions. Development of this technology will be applicable across many GI disorders where assessing subtle effects on the human immune system vnll be critical to understand safety and efficacy of clinical interventions, including trials of vaccinations, cellular therapy, drug therapy, cancer immunotherapy, transplantation, and autoimmune/inflammatory disorders.

当UNC胃肠道生物学和疾病中心最初建立 强调对上皮运输，Grovrth，开发和修复的分析，包括控制 这些功能通过上皮下免疫和间质细胞的功能。从一开始就被认可 能够测量可溶性信号分子水平的核心设施（例如肽 激素，生长因子，类花生素，细胞因子和环状核苷酸）对于对 追求这些目标的调查人员。因此，建立了免疫测定（IA）核心，并 由核心主任（Don Powell博士）和核心技术人员组成。 1991年，迈克尔·戈伊博士 取代了鲍威尔博士为IA核心主任。由于对核心服务的需求不断增加， 2002年聘请了额外的半场技术员。 2008年1月，斯科特·普莱维（Scott Plevy）取代了迈克尔·戈伊（Michael Goy）为IT核心总监。战略原因 为此，Plevy博士在细胞因子生物学和定量技术方面的专业知识 从历史上看，核心的主要用法。此外。 Plevy博士带来了新的 如上所述，生物标志物开发和免疫监测的专业知识将成为新的 根据CGIBD成员的预期需求，核心的计划。 2008年4月，卡尔顿 安德森（Anderson）成为新的IT核心技术员和助理主任。安德森先生提供了 丰富的实验室经验和专业知识。他最迅速地吸收了最多的技术 通常要求的ELISA，已接受所有现有设备的培训，并已在 Plevy博士的指导，核心的新成本有效技术。 与这些人员的变化并联，IT核心的目标也发展了， 扩展。由于该中心的重点已经从腹泻转变为炎症性疾病和癌症，所以 中心成员的需求发生了变化，IT核心已经获得了新的功能。从一个 针对一些调查人员执行的三个免疫测定的初始曲目，该核心现在为 超过50个实验室的客户群，提供各种服务，包括（a）50多个 ELISA和RIA测量的不同类型，（b）自定义免疫测定开发以及（c） 定量多重蛋白质组学分析，可以适用于众多应用。在 如本应用程序其他地方所述的最后一个资金周期，即IT的蛋白质组织成分 核心被消除。该决定反映了校园中多个核心的存在 成本效果蛋白质组学分析，并遵循CGIBD执行委员会的投票和批准 他得出结论认为，这种技术不再是重中之重。 为CGIBD社区提供扩展和更具成本效益的服务。 Plevy博士对最需要的细胞因子分析启动了新的细胞因子ELISA开发 在CGIBD研究者的实验室中建立了技术。安德森先生已经谈判 标准ELISA套件的价格更好；因此，CGIBD的调查人员立即受益于10- 提供的服务成本降低了35％。 随着对翻译研究的重视，IT核心已经开始了几个 新计划。由新的核心促进的IT核心向前迈进的重点 技术平台和主题一致的NIH路线图将是生物标志物 发展强调人类研究。我们现在正在执行多重蛋白 使用XMAP技术进行分析。我们已经协商了VNTH BIO-RAD和R和D系统Toreceive 核心的Bio-plex 200系统的多重套件的折现价格，该系统有助于人类 和鼠研究，并为生物标志物的发展做出贡献。此外，我们正在计划 现场研讨会以更好地熟悉多重平台。我们也有 与GlyCominds，Inc。建立合作，以开发基于ELISA的血清学标记 针对人类炎症性肠病（IBD）的肠菌群针对肠易激 综合征（IBS）和炎症性肝病。最后，由于最近资助的NIH和 行业赞助的几位中心调查员的活动，核心对 IBD患者的免疫监测，包括但不限于免疫原性和疫苗 治疗干预期间的监测以及免疫能力和重建。 该技术的开发将适用于许多胃肠病疾病，在其中评估微妙 对人免疫系统的影响对于了解临床的安全性和功效至关重要 干预措施，包括疫苗接种试验，细胞疗法，药物治疗，癌症免疫疗法， 移植和自身免疫/炎症性疾病。